VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4-4.004) | Synapse
April 9, 2024
VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4-4.004)
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
To examine the impact of the anti-human TREM2 agonistic mAb VHB937 in vitro and in vivo in models for neurodegenerative diseases.